boehringer glp-1 Boehringer, Zealand's MASH Data 'Unintentionally' Published by Medical Congress Website Obesity in the spotlight -
Description
Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus
As with any treatment, pregnant or breastfeeding women should consult their healthcare provider before using the patch to avoid any potential risks
That stability lines up with recent analyst debate around Q4 results, the updated 2026 outlook, and the role of LifeMD's GLP-1 focused virtual care program in shaping long term expectations
Inside the largest genetic study of GLP-1 response to date
SMGT-GLP-1, also known as semaglutide, is definitely a great treatment
